Skip to main content
Home
 
 
 
MENU
Home
Janssen’s COVID-19 Vaccine Status >

Janssen Global Main Menu

  • Our Company
    • About Us
    • Contact Us
    • Grants & Giving
    • News Center
    • Our Leaders
    • Patient Safety information
    • Products
    • Sustainability
    • Transparency
    • VISIT JANSSEN IN YOUR COUNTRY
  • Our Focus
    • Therapeutic Areas
    • Cardiovascular, Metabolism and Retina
    • Immunology
    • Infectious Diseases & Vaccines
    • Neuroscience
    • Oncology
    • Pulmonary Hypertension
    • Patient Engagement
  • Our Science
    • Our Response to COVID-19
    • Clinical Trials
    • Compassionate Use & Pre-Approval Access
    • R&D Data Science
    • Janssen Global Trial Finder
    • World Without Disease Accelerator
    • Janssen Clinical Innovation
    • Precision Medicine & Janssen Diagnostics

Our Stories List

Making a Splash for Disease Awareness
Global_Trial_Finder
Making a Splash for Disease Awareness
Looking Under the Hood for Green Chemistry Solutions
Global_Trial_Finder
Looking Under the Hood for Green Chemistry Solutions
  • Return to home

Global Trial Finder

  • text size

My Saved Trials

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (COPERNICUS)

Last Updated   May 14, 2025

Want to learn how to participate in this trial?

61186372NSC2012

OVERVIEW

  • Sexes Eligible for Study
    all
  • Age
    18+ years
  • Phase
    phase 2
    2
  • Sites
    95 Sites
  • Status
    Recruiting

SUMMARY

The primary purpose of the study is to assess how well amivantamab subcutaneous (SC) administration in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC; that is one of the major types of lung cancer).

CONDITIONS

  • Carcinoma, Non-Small-Cell Lung

ELIGIBILITY


Inclusion Criteria:

* Have histologically or cytologically confirmed advanced or metastatic non-small cell lung cancer (NSCLC) that is not amenable to curative intent therapy
* Epidermal growth factor resistance-mutation (EGFRm) must be an Ex19del or Ex21 L858R substitution, as detected by food and drug administration (FDA)-approved or other validated test in a clinical laboratory improvement amendments (CLIA)-certified laboratory in accordance with site standard of care
* Have at least 1 measurable lesion, according to RECIST version (v)1.1, that has not been previously irradiated
* Any toxicities from prior systemic anticancer therapy must have resolved to national cancer institute common terminology criteria for adverse events (NCI-CTCAE) version 5.0 grade 1 or baseline level (except for alopecia [any grade], grade <=2 peripheral neuropathy, or grade <=2 hypothyroidism stable on hormone replacement)
* Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1


Exclusion Criteria:

* Medical history of active interstitial lung disease (ILD), including drug-induced ILD or radiation pneumonitis
* Had major surgery excluding placement of vascular access or tumor biopsy or had significant traumatic injury within 4 weeks before the first dose of anticancer treatments or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study
* Participant has uncontrolled tumor-related pain (symptomatic lesions amenable to palliative radiotherapy should be treated prior to first dosing)
* Received an investigational treatment that has not been cleared (based on at least 5 half lives of any pharmaceutical treatment) or within 12 months before the planned first dose of study treatment or is currently enrolled in an investigational study
* Has a prior or concurrent second malignancy (other than the disease under study) which natural history or treatment could likely interfere with any study endpoints of safety or the efficacy of the study treatment(s)


Inclusion Criteria:

* Have histologically or cytologically confirmed advanced or metastatic non-small cell lung cancer (NSCLC) that is not amenable to curative intent therapy
* Epidermal growth factor resistance-mutation (EGFRm) must be an Ex19del or Ex21 L858R substitution, as d

More...

DETAILS

LOCATIONS

Locations in:
United States, Puerto Rico
Country (2) City or Province (95) Status
United States Los Alamitos Cancer and Blood Specialty Clinic
RECRUITING
United States Santa Rosa Providence Medical Foundation
RECRUITING
United States Hinsdale Hope and Healing Cancer Services
RECRUITING
United States Wilson Regional Medical Oncology Center
RECRUITING
United States El Paso Renovatio Clinical
RECRUITING
United States Kingwood Community Clinical Trials
RECRUITING
United States The Woodlands Renovatio Clinical
RECRUITING
United States Fullerton Providence Medical Foundation
RECRUITING
United States Glendale The Oncology Institute of Hope and Innovation
RECRUITING
United States Glendale Oncology Physicians Network Healthcare
RECRUITING
United States Glendale Los Angeles Cancer Network
RECRUITING
United States Los Angeles USC Norris Comprehensive Cancer Center
RECRUITING
United States Los Angeles Cedars Sinai Medical Center
RECRUITING
United States Los Angeles Valkyrie Clinical Trials
RECRUITING
United States Orange St. Joseph Hospital Center for Cancer Prevention and Treatment
RECRUITING
United States Walnut Creek John Muir Health Clinical Research Center
RECRUITING
United States New Haven Yale New Haven Hospital Yale Cancer Center
RECRUITING
United States Orlando Orlando Health Cancer Institute
RECRUITING
United States Atlanta Piedmont Healthcare
RECRUITING
United States Atlanta Piedmont Cancer Institute
RECRUITING
United States Atlanta Winship Cancer Institute Emory University
RECRUITING
United States Noblesville Investigative Clinical Research of Indiana, LLC
RECRUITING
United States Ames Accellacare of McFarland
RECRUITING
United States Ypsilanti Trinity Health St Joseph Mercy Ann Arbor
RECRUITING
United States Minneapolis University Of Minnesota
RECRUITING
United States Jackson Jackson Oncology Associates
RECRUITING
United States Saint Louis Washington University School Of Medicine
RECRUITING
United States Flemington Hunterdon Hematology Oncology
RECRUITING
United States New Brunswick Rutgers Cancer Institute of New Jersey
RECRUITING
United States New York NYU Langone Health Laura and Isaac Perlmutter Cancer Center
RECRUITING
United States New York Herbert Irving Comprehensive Cancer Center Columbia University Medical Center
RECRUITING
United States Schenectady Ellis Hospital
RECRUITING
United States Westbury Clinical Research Alliance Inc
RECRUITING
United States Sioux Falls Avera Medical Group
RECRUITING
United States Memphis Baptist Cancer Center
RECRUITING
United States Dallas UT Southwestern Medical Center
RECRUITING
United States Fort Worth JPS Health Network
RECRUITING
United States Spokane Summit Cancer Centers
RECRUITING
Puerto Rico San Juan Auxilio Mutuo Cancer Center
RECRUITING
United States Huntsville Clearview Cancer Institute
RECRUITING
United States Goodyear Cancer Treatment Center of America Phoenix
RECRUITING
United States Corona City of Hope Corona
RECRUITING
United States Duarte City of Hope
RECRUITING
United States Glendale Glendale Adventist Medical Center
RECRUITING
United States Greenbrae Marin Cancer Center
RECRUITING
United States Huntington Beach City of Hope Seacliff
RECRUITING
United States Irvine City of Hope Orange County Lennar Foundation Cancer Center
RECRUITING
United States Lancaster City of Hope Antelope Valley
RECRUITING
United States Long Beach City of Hope Long Beach Elm
RECRUITING
United States Murrieta Valkyrie Clinical Trials
RECRUITING
United States Oakland Kaiser Permanente Oakland Medical Center
RECRUITING
United States Orange University of California Irvine
RECRUITING
United States Roseville Kaiser Permanente Roseville Medical Center
RECRUITING
United States San Francisco Kaiser Permanente San Francisco Medical Center
RECRUITING
United States San Francisco UCSF Zuckerberg San Francisco General Hospital
RECRUITING
United States Santa Clara Kaiser Permanente Santa Clara Medical Center
RECRUITING
United States South Pasadena City of Hope South Pasadena
RECRUITING
United States Upland City of Hope Upland
RECRUITING
United States Vallejo Kaiser Permanente Northern California
RECRUITING
United States Walnut Creek Kaiser Permanente Walnut Creek Medical Center
RECRUITING
United States Washington MedStar Georgetown University Hospital
RECRUITING
United States Washington Washington DC VA Medical Center
RECRUITING
United States Fort Lauderdale The Oncology Institute of Hope and Innovation
RECRUITING
United States Tampa Moffitt Cancer Center
RECRUITING
United States Atlanta Grady Health System Correll Pavilion
RECRUITING
United States Newnan City of Hope Cancer Center
RECRUITING
United States Chicago University of Illinois at Chicago
RECRUITING
United States Decatur Cancer Care Specialists of Central Illinois
RECRUITING
United States Zion City of Hope Chicago
RECRUITING
United States Fort Wayne Fort Wayne Medical Oncology and Hematology
RECRUITING
United States Silver Spring Maryland Oncology Hematology P A
RECRUITING
United States Boston Boston University Medical Center
RECRUITING
United States Springfield Oncology Hematology Associates
RECRUITING
United States Morristown Morristown Medical Center
RECRUITING
United States Summit Overlook Medical Center
RECRUITING
United States Teaneck Holy Name Medical Center
RECRUITING
United States Albuquerque University of New Mexico
RECRUITING
United States Bronx Montefiore Medical Center
RECRUITING
United States East Syracuse Hematology-Oncology Associates of CNY
RECRUITING
United States Mineola Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island
RECRUITING
United States Shirley New York Cancer and Blood Specialists
RECRUITING
United States Eugene Oncology Associates of Oregon PC Willamette Valley Cancer Institute
RECRUITING
United States Portland Oregon Health And Science University
RECRUITING
United States West Reading McGlinn Cancer Institute Reading Hospital
RECRUITING
United States Chattanooga Tennessee Oncology
RECRUITING
United States Knoxville University of Tennessee
RECRUITING
United States Nashville SCRI Oncology Partners
RECRUITING
United States Nashville Tennessee Oncology
RECRUITING
United States Dallas Texas Oncology P A
RECRUITING
United States Houston MD Anderson Cancer Center
RECRUITING
United States Houston Oncology Consultants Texas
RECRUITING
United States Tyler The University of Texas Health Science Center at Tyler
RECRUITING
United States Salt Lake City Huntsman Cancer Institute
RECRUITING
United States Olympia Vista Oncology
RECRUITING
United States Vancouver Northwest Cancer Specialists - Vancouver
RECRUITING
Show More
Geo Locations

33.80307, -118.07256

38.44047, -122.71443

41.80086, -87.93701

35.72127, -77.91554

31.75872, -106.48693

30.03355, -95.26104

30.15799, -95.48938

33.87029, -117.92534

34.14251, -118.25508

34.14251, -118.25508

34.14251, -118.25508

34.05223, -118.24368

34.05223, -118.24368

34.05223, -118.24368

33.78779, -117.85311

37.90631, -122.06496

41.30815, -72.92816

28.53834, -81.37924

33.749, -84.38798

33.749, -84.38798

33.749, -84.38798

40.04559, -86.0086

42.03471, -93.61994

42.24115, -83.61299

44.97997, -93.26384

32.29876, -90.18481

38.62727, -90.19789

40.51233, -74.85933

40.48622, -74.45182

40.71427, -74.00597

40.71427, -74.00597

42.81424, -73.93957

40.75566, -73.58763

43.54997, -96.70033

35.14953, -90.04898

32.78306, -96.80667

32.72541, -97.32085

47.65966, -117.42908

18.46633, -66.10572

34.7304, -86.58594

33.43532, -112.35821

33.87529, -117.56644

34.13945, -117.97729

34.14251, -118.25508

37.94854, -122.5247

33.6603, -117.99923

33.66946, -117.82311

34.69804, -118.13674

33.76696, -118.18923

33.55391, -117.21392

37.80437, -122.2708

33.78779, -117.85311

38.75212, -121.28801

37.77493, -122.41942

37.77493, -122.41942

37.35411, -121.95524

34.11612, -118.15035

34.09751, -117.64839

38.10409, -122.25664

37.90631, -122.06496

38.89511, -77.03637

38.89511, -77.03637

26.12231, -80.14338

27.94752, -82.45843

33.749, -84.38798

33.38067, -84.79966

41.85003, -87.65005

39.84031, -88.9548

42.44613, -87.83285

41.1306, -85.12886

38.99067, -77.02609

42.35843, -71.05977

37.21533, -93.29824

40.79677, -74.48154

40.71562, -74.36468

40.8976, -74.01597

35.08449, -106.65114

40.84985, -73.86641

43.06534, -76.07853

40.74927, -73.64068

40.80149, -72.8676

44.05207, -123.08675

45.52345, -122.67621

40.3337, -75.94743

35.04563, -85.30968

35.96064, -83.92074

36.16589, -86.78444

36.16589, -86.78444

32.78306, -96.80667

29.76328, -95.36327

29.76328, -95.36327

32.35126, -95.30106

40.76078, -111.89105

47.03787, -122.9007

45.63873, -122.66149

x
50

Indicates 50+ sites in this region: click to zoom in.

10

Indicates 10+ sites in this region: click to zoom in.

5

Indicates < 10 sites in this region: click to zoom in.

Corresponds to individual site.

Interested in participating?

×

Confirm


If you are interested in this clinical trial, we will use your email address to respond to your questions and fulfill your requests as necessary for our legitimate interest and possibly to comply with our legal obligations relating to pharmacovigilance. Please read our Privacy Policy.

Footer

  • PRIVACY POLICY
  • LEGAL NOTICE
  • COOKIE POLICY
  • COOKIE SETTINGS
  • CAREERS
  • NEWS CENTER
  • DO NOT SELL MY PERSONAL INFORMATION

Footer Social

Find Janssen Global on:

twitter youtube linkedin

Janssen Global Policy text

©Johnson & Johnson Innovative Medicine. All Rights Reserved. This website is hosted and operated by Johnson & Johnson Innovative Medicine, which is solely responsible for its content. This website is intended for a global audience.